Table 1.
Clinical baseline characteristic and medication data of participants by quartiles of hs-CRP.
| Variable |
Quartile of hs-CRP in CCS patients |
|||||
|---|---|---|---|---|---|---|
| Total |
1st quartile CRP <0.7 |
2nd quartile 0.7≤CRP<1.34 |
3rd quartile 1.34≤CRP <2.72 |
4th quartile CRP ≥2.72 |
||
| (n = 4083) | (n = 1009) | (n = 1030) | (n = 1028) | (n = 1016) | p value | |
| Age (years) | 58.3 ± 10.1 | 58.1 ± 9.8 | 57.6 ± 10.1 | 58.5 ± 10.2 | 59.2 ± 10.4 | 0.002 |
| Sex (male, %) | 3172 (77.7) | 809 (80.2) | 800 (77.7) | 799 (77.7) | 764 (75.2) | 0.064 |
| Body mass index (kg/m2) | 26.0 ± 3.2 | 25.3 ± 3.1 | 25.9 ± 2.9 | 26.3 ± 3.2 | 26.5 ± 3.3 | <0.001 |
| Left ventricular ejection fraction (%) | 63.5 ± 7.1 | 63.7 ± 6.8 | 63.8 ± 6.8 | 63.4 ± 7.1 | 63.0 ± 7.7 | 0.102 |
| Chronic kidney disease (n, %) | 130 (3.2) | 17 (1.7) | 25 (2.4) | 26 (2.5) | 62 (6.1) | <0.001 |
| Hypertension (n, %) | 2685 (65.8) | 586 (58.1) | 685 (66.5) | 694 (67.5) | 720 (70.9) | <0.001 |
| Hyperlipidemia (n, %) | 2839 (69.5) | 680 (67.4) | 730 (70.9) | 726 (70.6) | 703 (69.2) | 0.297 |
| Diabetes mellitus (n, %) | 1316 (32.2) | 284 (28.1) | 334 (32.4) | 323 (31.4) | 375 (36.9) | <0.001 |
| Hyperuricemia (n, %) | 778 (19.1) | 124 (12.3) | 187 (18.2) | 223 (21.7) | 244 (24.0) | <0.001 |
| Current smoker (n, %) | 2251 (55.1) | 523 (51.8) | 549 (53.3) | 591 (57.5) | 588 (57.9) | 0.011 |
| Family history of coronary artery disease (n, %) | 1006 (24.6) | 251 (24.9) | 246 (23.9) | 263 (25.6) | 246 (24.2) | 0.816 |
| Stroke history (n, %) | 433 (10.6) | 99 (9.8) | 96 (9.3) | 116 (11.3) | 122 (12.0) | 0.167 |
| Peripheral artery disease (n, %) | 138 (3.4) | 35 (3.5) | 32 (3.1) | 30 (2.9) | 41 (4.0) | 0.519 |
| Old myocardial infarction (n, %) | 1151 (28.2) | 298 (29.5) | 295 (28.6) | 284 (27.6) | 274 (27.0) | 0.590 |
| Previous PCI (n, %) | 1181 (28.9) | 327 (32.4) | 324 (31.5) | 268 (26.1) | 262 (25.8) | <0.001 |
| Previous CABG (n, %) | 187 (4.6) | 47 (4.7) | 40 (3.9) | 46 (4.5) | 54 (5.3) | 0.486 |
| Medication (cases, %) | ||||||
| Aspirin | 4037 (98.9) | 993 (98.4) | 1018 (98.8) | 1022 (99.4) | 1004 (98.9) | 0.198 |
| Clopidogrel | 4032 (98.8) | 994 (98.5) | 1015 (98.5) | 1019 (99.1) | 1004 (98.8) | 0.568 |
| DAPT | 3988 (97.7) | 979 (97.0) | 1003 (97.4) | 1014 (98.6) | 992 (97.6) | 0.091 |
| Statin | 3922 (96.1) | 975 (96.6) | 979 (95.0) | 993 (96.6) | 975 (96.0) | 0.217 |
| Β-blocker | 3764 (92.2) | 914 (90.6) | 959 (93.1) | 950 (92.4) | 941 (92.6) | 0.162 |
| Lesions involving LM | 110 (2.7) | 23 (2.3) | 18 (1.7) | 32 (3.1) | 37 (3.6) | 0.039 |
| Lesions involving LAD | 3676 (90.0) | 922 (91.4) | 924 (89.7) | 937 (91.1) | 893 (87.9) | 0.033 |
| Lesions involving LCX | 702 (17.2) | 150 (14.9) | 166 (16.1) | 174 (16.9) | 212 (20.9) | 0.002 |
| Lesions involving RCA | 917 (22.5) | 248 (24.6) | 234 (22.7) | 225 (21.9) | 210 (20.7) | 0.195 |
| SYNTAX score | ||||||
| ≤22 | 3587 (87.9) | 896 (88.8) | 918 (89.1) | 900 (87.5) | 873 (85.9) | 0.110 |
| 23-32 | 421 (10.3) | 102 (10.1) | 92 (8.9) | 104 (10.1) | 123 (12.1) | 0.125 |
| ≥33 | 75 (1.8) | 11 (1.1) | 20 (1.9) | 24 (2.3) | 20 (2.0) | 0.196 |
| HbA1c (%) | 6.6 ± 1.2 | 6.4 ± 1.0 | 6.6 ± 1.2 | 6.7 ± 1.2 | 6.9 ± 1.4 | <0.001 |
| hs-CRP (mg/L) | 2.44 ± 3.02 | 0.39 ± 0.20 | 0.98 ± 0.18 | 1.88 ± 0.38 | 6.51 ± 3.64 | <0.001 |
CCS, chronic coronary syndromes; PCI, Percutaneous coronary intervention; CABG, coronary artery bypass grafting; DAPT, dual antiplatelet treatment; LM, left main; LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; SYNTAX, the synergy between percutaneous coronary intervention with Taxus and cardiac surgery; HbA1c, hemoglobin, type A1C; hs-CRP, high –C reaction protein.